{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:52:25Z","timestamp":1793055145469,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim. Care Respir. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The British Thoracic Society (BTS) Guidelines for Bronchiectasis in adults were published in January 2019, and comprise recommendations for treatment from primary to tertiary care. Here, we outline the practical implications of these guidelines for primary care practitioners. A diagnosis of bronchiectasis should be considered when a patient presents with a recurrent or persistent (&gt;8 weeks) productive cough. A definitive diagnosis is made by using thin-section chest computed tomography (CT). Once diagnosed, patients should be initially assessed by a specialist respiratory team and a shared management plan formulated with the patient, the specialist and primary care teams. The cornerstone of primary care management is physiotherapy to improve airway sputum clearance and maximise exercise capacity, with prompt treatment of acute exacerbations with antibiotics.<\/jats:p>","DOI":"10.1038\/s41533-019-0136-8","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T10:02:45Z","timestamp":1561629765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Primary care implications of the British Thoracic Society Guidelines for bronchiectasis in adults 2019"],"prefix":"10.1038","volume":"29","author":[{"given":"Kevin","family":"Gruffydd-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Keeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikki","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Recabarren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita L.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Loebinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizzie","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Welham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"key":"136_CR1","doi-asserted-by":"crossref","unstructured":"Hill, A. T. et al. British Thoracic Guideline for bronchiectasis in adults. Thorax. 74(Suppl 1), 1\u201369 (2019).","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"136_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/13993003.01033-2015","volume":"47","author":"JK Quint","year":"2016","unstructured":"Quint, J. K. et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population\u2010based cohort study. Eur. Respir. J. 47, 186\u2013193 (2016).","journal-title":"Eur. Respir. J."},{"key":"136_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1479972317709649","volume":"14","author":"D Weycker","year":"2013","unstructured":"Weycker, D. et al. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults. 2013 Chronic Respir. Dis. 14, 377\u2013384 (2013).","journal-title":"2013 Chronic Respir. Dis."},{"issue":"Suppl 1","key":"136_CR4","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2010.136119","volume":"65","author":"M. C. Pasteur","year":"2010","unstructured":"Pasteur, M. C. et al. British Thoracic Society Guidelines for non-cystic fibrosis bronchiectasis. Thorax. 65(Suppl 1), i1\u2013i58 (2010).","journal-title":"Thorax"},{"key":"136_CR5","unstructured":"British Thoracic Society Standards of Care Committee Guideline Production Manual 2016. www.brit-thoracic.org.uk (2016)."},{"key":"136_CR6","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50: a Guideline Developer\u2019s Handbook. (SIGN: Edinburgh, 2003)."},{"key":"136_CR7","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/COPD.S83910","volume":"10","author":"Y Ni","year":"2015","unstructured":"Ni, Y. et al. Clinical characteristics of patients with chronic obstructive pulmonary disease and bronchiectasis: a systematic review and meta-analysis. Int J. Chron. Pulmon Dis. 10, 1465\u20131475 (2015).","journal-title":"Int J. Chron. Pulmon Dis."},{"key":"136_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/thorax.55.8.635","volume":"55","author":"C O\u2019Brien","year":"2000","unstructured":"O\u2019Brien, C. et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 55, 635\u2013642 (2000).","journal-title":"Thorax."},{"key":"136_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1378\/chest.09-0174","volume":"136","author":"S Gupta","year":"2009","unstructured":"Gupta, S. et al. Qualitative analysis of high\u2010resolution CT scans in severe asthma. Chest 136, 1521\u20131528 (2009).","journal-title":"Chest"},{"key":"136_CR10","first-page":"531","volume":"64","author":"J Allain","year":"1997","unstructured":"Allain, J. et al. Prevalence of symptomatic bronchiectasis in patients with rheumatoid arthritis. Rev. Rheum. Eng. Ed. 64, 531\u2013537 (1997).","journal-title":"Rev. Rheum. Eng. Ed."},{"key":"136_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1378\/chest.06-1074","volume":"131","author":"H Black","year":"2007","unstructured":"Black, H., Mendoza, M. & Murin, S. Thoracic manifestations of inflammatory Bowel disease. Chest 131, 524\u2013532 (2007).","journal-title":"Chest"},{"key":"136_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.rmed.2006.11.008","volume":"101","author":"A Shoemark","year":"2007","unstructured":"Shoemark, A., Ozerovitch, L. & Wilson, R. Aetiology in adult patients with bronchiectasis. Respir. Med. 101, 1163\u20131170 (2007).","journal-title":"Respir. Med."},{"key":"136_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/028418519103200601","volume":"32","author":"KA Young","year":"1991","unstructured":"Young, K. A. & Kolbenstvedt, A. High resolution CT and bronchography in the assessment of bronchiectasis. Acta Radiol. 32, 439\u2013441 (1991).","journal-title":"Acta Radiol."},{"issue":"4 Pt 1","key":"136_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1164\/ajrccm.162.4.9906120","volume":"162","author":"MC Pasteur","year":"2000","unstructured":"Pasteur, M. C. et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 162(4 Pt 1), 1277\u20131284 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"136_CR15","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1513\/AnnalsATS.201507-472OC","volume":"2","author":"S Lonni","year":"2015","unstructured":"Lonni, S. et al. Etiology of non-cystic fibrosis bronchiectasis in adults and it\u2019s correlation to disease severity. Ann. Am. Thorac. Soc. 2, 1764\u20131770 (2015).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"136_CR16","first-page":"S15","volume":"22","author":"JT Rees","year":"2013","unstructured":"Rees, J. T. et al. Managing urinary incontinence in adults with bronchiectasis. Br. J. Nurs. 22, S15\u2013S16 (2013). S18.","journal-title":"Br. J. Nurs."},{"key":"136_CR17","unstructured":"BTS\/SIGN Guideline for the management of asthma. www.brit-thoracic.org.uk\/standards-of-care\/guidelines\/btssign-british-guideline-on-the-management-of-asthma (2016)."},{"key":"136_CR18","unstructured":"National Institute of Health and Care Excellence (NICE) Guideline NG115 December 2018: Chronic Obstructive Pulmonary disease in over 16\u2019s. Diagnosis and management. www.nice.org.uk\/guidance\/ng115 (2018)."},{"key":"136_CR19","unstructured":"Global Initiative for Chronic Lung Disease (GOLD) Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Obstructive Disease. www.goldcopd.org (2019)."},{"key":"136_CR20","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. www.ginasthma.org (2018)."},{"key":"136_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.rmed.2013.04.006","volume":"107","author":"P Mandal","year":"2013","unstructured":"Mandal, P. et al. Symptoms of airway reflux predict exacerbations an quality of life in bronchiectais. Respir. Med. 107, 1008\u20131013 (2013).","journal-title":"Respir. Med."},{"key":"136_CR22","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1183\/09031936.00055509","volume":"34","author":"MP Murray","year":"2009","unstructured":"Murray, M. P. et al. A randomised crossover trial of chest physiotherapy in non\u2010cystic fibrosis bronchiectasis. Eur. Respir. J. 34, 1086\u20131092 (2009).","journal-title":"Eur. Respir. J."},{"key":"136_CR23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1742-1241.2002.tb11186.x","volume":"56","author":"B O\u2019Neill","year":"2002","unstructured":"O\u2019Neill, B. et al. current physiotherapy management of patients with bronchiectasis: a UK survey. Int J. Clin. Pract. 56, 34\u201335 (2002).","journal-title":"Int J. Clin. Pract."},{"issue":"1","key":"136_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1465-9921-15-44","volume":"15","author":"Annemarie L Lee","year":"2014","unstructured":"Lee, A. L. et al. The short and long term effects of exercise training in non\u2010cystic fibrosis bronchiectasis; a randomized controlled trial. Respir. Res. 15, 44 (2014).","journal-title":"Respiratory Research"},{"key":"136_CR25","first-page":"CD002733","volume":"2006","author":"PJ Poole","year":"2006","unstructured":"Poole, P. J. et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006, CD002733 (2006).","journal-title":"Cochrane Database Syst. Rev."},{"key":"136_CR26","volume":"213","author":"S Moberley","year":"2013","unstructured":"Moberley, S. et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 213, CD000422 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"136_CR27","doi-asserted-by":"crossref","unstructured":"Kapur, N. et al. Inhaled steroids for bronchiectasis. Cochrane Database Syst. Rev. 86, CD000996 (2009).","DOI":"10.1002\/14651858.CD000996.pub2"},{"key":"136_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/thx.33.5.635","volume":"33","author":"S Nogrady","year":"1978","unstructured":"Nogrady, S. et al. Reversibility of airways obstruction in bronchiectasis. Thorax. 33, 635\u2013637 (1978).","journal-title":"Thorax."},{"key":"136_CR29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2013.1937","volume":"309","author":"J Altenburg","year":"2013","unstructured":"Altenburg, J. et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non\u2010cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309, 1251\u20131259 (2013).","journal-title":"JAMA"},{"key":"136_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ejim.2003.10.002","volume":"14","author":"MG Kelly","year":"2003","unstructured":"Kelly, M. G., Murphy, S. & Elborn, J. S. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur. J. Intern Med. 2003 14, 488\u2013492 (2003).","journal-title":"Eur. J. Intern Med. 2003"},{"key":"136_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.rmed.2013.12.015","volume":"108","author":"PC Goeminne","year":"2014","unstructured":"Goeminne, P. C. et al. Mortality in non\u2010cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir. Med. 108, 287\u2013296 (2014).","journal-title":"Respir. Med."},{"key":"136_CR32","unstructured":"British Thoracic Society Guidelines for management of community acquired pneumonia. www.brit-thoracic.org.uk\/document-library\/clinical-information\/pneumonia\/adult-pneumonia\/a-quick-reference-guide-bts-guidelines-for-the-management-of-community-acquired-pneumonia-in-adults (2009)."},{"key":"136_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/thx.36.9.659","volume":"36","author":"DA Ellis","year":"1981","unstructured":"Ellis, D. A. et al. Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax. 36, 659\u2013664 (1981).","journal-title":"Thorax."},{"key":"136_CR34","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino, E. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 50, 1700629 (2017).","journal-title":"Eur. Respir. J."}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-019-0136-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-019-0136-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-019-0136-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T20:16:23Z","timestamp":1694981783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-019-0136-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1038\/s41533-019-0136-8","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"18 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.G.J. has declared funding from Boehringer Ingelheim, GlaxoSmithkline, Astra Zeneca, Napp, TEVA, Chiesi, Nutricia and Novartis. M.R.L. has declared funding from Astra Zeneca, Bayer Healthcare, Insmed, Pulmocide, Griffols, Polyphor and Savara. V.K. has declared funding for educational sessions from Astra Zeneca, Napp, Chiesi, Pfizer, Boehringer Ingelheim, TEVA and GSK. A.T.H., D.K., A.L.S., K.P., A.H., L.G., X.R., A.W. and S.A.W. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}